COCP Annual EBITDA
-$21.16 M
-$3.41 M-19.21%
31 December 2023
Summary:
As of January 21, 2025, COCP annual earnings before interest, taxes, depreciation & amortization is -$21.16 million, with the most recent change of -$3.41 million (-19.21%) on December 31, 2023. During the last 3 years, it has fallen by -$11.68 million (-123.13%). COCP annual EBITDA is now -4742.17% below its all-time high of $455.80 thousand, reached on December 31, 2010.COCP EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
COCP Quarterly EBITDA
-$4.94 M
+$294.00 K+5.61%
30 September 2024
Summary:
As of January 21, 2025, COCP quarterly earnings before interest, taxes, depreciation & amortization is -$4.94 million, with the most recent change of +$294.00 thousand (+5.61%) on September 30, 2024. Over the past year, it has increased by +$992.00 thousand (+16.71%). COCP quarterly EBITDA is now -264.77% below its all-time high of $3.00 million, reached on March 31, 2019.COCP Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
COCP TTM EBITDA
-$19.97 M
+$992.00 K+4.73%
30 September 2024
Summary:
As of January 21, 2025, COCP TTM earnings before interest, taxes, depreciation & amortization is -$19.97 million, with the most recent change of +$992.00 thousand (+4.73%) on September 30, 2024. Over the past year, it has dropped by -$386.00 thousand (-1.97%). COCP TTM EBITDA is now -2888.19% below its all-time high of $716.20 thousand, reached on September 30, 2010.COCP TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
COCP EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -19.2% | +16.7% | -2.0% |
| 3 y3 years | -123.1% | -12.3% | -12.5% |
| 5 y5 years | +66.2% | -12.3% | -12.5% |
COCP EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -53.3% | at low | -37.8% | +16.7% | -44.7% | +4.7% |
| 5 y | 5-year | -123.1% | +56.0% | -241.8% | +89.7% | -110.6% | +64.3% |
| alltime | all time | -4742.2% | +80.0% | -264.8% | +94.9% | -2888.2% | +81.5% |
Cocrystal Pharma EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$4.94 M(-5.6%) | -$19.97 M(-4.7%) |
| June 2024 | - | -$5.24 M(+27.0%) | -$20.96 M(+5.3%) |
| Mar 2024 | - | -$4.12 M(-27.2%) | -$19.91 M(-4.5%) |
| Dec 2023 | -$21.16 M(+19.2%) | -$5.67 M(-4.5%) | -$20.85 M(+6.5%) |
| Sept 2023 | - | -$5.93 M(+41.8%) | -$19.58 M(+1.8%) |
| June 2023 | - | -$4.18 M(-17.3%) | -$19.24 M(+2.9%) |
| Mar 2023 | - | -$5.06 M(+15.0%) | -$18.70 M(+5.4%) |
| Dec 2022 | -$17.75 M(+28.6%) | -$4.40 M(-21.3%) | -$17.75 M(+4.8%) |
| Sept 2022 | - | -$5.60 M(+53.7%) | -$16.94 M(+11.6%) |
| June 2022 | - | -$3.64 M(-11.5%) | -$15.18 M(-0.2%) |
| Mar 2022 | - | -$4.11 M(+14.6%) | -$15.22 M(+10.3%) |
| Dec 2021 | -$13.80 M(+45.5%) | -$3.59 M(-6.6%) | -$13.80 M(+18.4%) |
| Sept 2021 | - | -$3.84 M(+4.5%) | -$11.66 M(+11.7%) |
| June 2021 | - | -$3.68 M(+36.6%) | -$10.44 M(+2.2%) |
| Mar 2021 | - | -$2.69 M(+86.2%) | -$10.22 M(+7.7%) |
| Dec 2020 | -$9.48 M(-80.3%) | -$1.45 M(-44.9%) | -$9.48 M(-83.0%) |
| Sept 2020 | - | -$2.62 M(-24.1%) | -$55.85 M(+1.6%) |
| June 2020 | - | -$3.46 M(+76.5%) | -$54.98 M(+3.7%) |
| Mar 2020 | - | -$1.96 M(-95.9%) | -$53.01 M(+10.3%) |
| Dec 2019 | -$48.05 M(-23.1%) | -$47.81 M(+2630.6%) | -$48.05 M(-15.2%) |
| Sept 2019 | - | -$1.75 M(+17.7%) | -$56.63 M(-1.0%) |
| June 2019 | - | -$1.49 M(-149.6%) | -$57.22 M(-0.6%) |
| Mar 2019 | - | $3.00 M(-105.3%) | -$57.59 M(-7.9%) |
| Dec 2018 | -$62.52 M(+666.1%) | -$56.40 M(+2310.1%) | -$62.52 M(+688.2%) |
| Sept 2018 | - | -$2.34 M(+25.9%) | -$7.93 M(+3.3%) |
| June 2018 | - | -$1.86 M(-3.4%) | -$7.68 M(+9.8%) |
| Mar 2018 | - | -$1.93 M(+6.5%) | -$6.99 M(-7.9%) |
| Dec 2017 | -$8.16 M(-92.3%) | -$1.81 M(-13.3%) | -$7.59 M(-92.6%) |
| Sept 2017 | - | -$2.08 M(+77.6%) | -$102.44 M(+0.2%) |
| June 2017 | - | -$1.17 M(-53.4%) | -$102.18 M(-2.8%) |
| Mar 2017 | - | -$2.52 M(-97.4%) | -$105.16 M(-2.6%) |
| Dec 2016 | -$105.62 M | -$96.66 M(+5178.9%) | -$107.92 M(+94.2%) |
| Sept 2016 | - | -$1.83 M(-55.9%) | -$55.57 M(-3.0%) |
| June 2016 | - | -$4.15 M(-21.4%) | -$57.29 M(+0.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2016 | - | -$5.28 M(-88.1%) | -$56.91 M(+5.9%) |
| Dec 2015 | -$53.76 M(+859.9%) | -$44.31 M(+1150.0%) | -$53.76 M(+386.2%) |
| Sept 2015 | - | -$3.54 M(-6.1%) | -$11.06 M(+27.3%) |
| June 2015 | - | -$3.77 M(+77.8%) | -$8.68 M(+39.0%) |
| Mar 2015 | - | -$2.12 M(+31.5%) | -$6.25 M(+11.6%) |
| Dec 2014 | -$5.60 M(+45.6%) | -$1.61 M(+37.8%) | -$5.60 M(+14.0%) |
| Sept 2014 | - | -$1.17 M(-12.3%) | -$4.91 M(+4.8%) |
| June 2014 | - | -$1.34 M(-9.4%) | -$4.69 M(+8.4%) |
| Mar 2014 | - | -$1.48 M(+58.9%) | -$4.32 M(+12.4%) |
| Dec 2013 | -$3.85 M(+70.0%) | -$928.00 K(-1.9%) | -$3.84 M(-32.8%) |
| Sept 2013 | - | -$946.00 K(-2.7%) | -$5.72 M(+33.3%) |
| June 2013 | - | -$972.00 K(-2.6%) | -$4.29 M(+48.2%) |
| Mar 2013 | - | -$998.00 K(-64.4%) | -$2.90 M(+48.0%) |
| Dec 2012 | -$2.26 M(-38.5%) | -$2.81 M(-682.2%) | -$1.96 M(+1909.3%) |
| Sept 2012 | - | $482.20 K(+13.6%) | -$97.50 K(-96.2%) |
| June 2012 | - | $424.40 K(-825.5%) | -$2.59 M(-23.5%) |
| Mar 2012 | - | -$58.50 K(-93.8%) | -$3.38 M(+7.3%) |
| Dec 2011 | -$3.68 M(-907.2%) | -$945.60 K(-53.0%) | -$3.15 M(+16.0%) |
| Sept 2011 | - | -$2.01 M(+444.2%) | -$2.72 M(+718.1%) |
| June 2011 | - | -$369.50 K(-314.0%) | -$332.40 K(-184.9%) |
| Mar 2011 | - | $172.70 K(-133.8%) | $391.60 K(+81.9%) |
| Dec 2010 | $455.80 K(-1172.5%) | -$511.70 K(-236.1%) | $215.30 K(-69.9%) |
| Sept 2010 | - | $376.10 K(+6.1%) | $716.20 K(+114.9%) |
| June 2010 | - | $354.50 K(<-9900.0%) | $333.30 K(-1265.4%) |
| Mar 2010 | - | -$3600.00(-66.7%) | -$28.60 K(-32.7%) |
| Dec 2009 | -$42.50 K(-23.6%) | -$10.80 K(+58.8%) | -$42.50 K(+4.7%) |
| Sept 2009 | - | -$6800.00(-8.1%) | -$40.60 K(-5.6%) |
| June 2009 | - | -$7400.00(-57.7%) | -$43.00 K(-15.5%) |
| Mar 2009 | - | -$17.50 K(+96.6%) | -$50.90 K(-8.5%) |
| Dec 2008 | -$55.60 K(-9.6%) | -$8900.00(-3.3%) | -$55.60 K(-22.2%) |
| Sept 2008 | - | -$9200.00(-39.9%) | -$71.50 K(-22.4%) |
| June 2008 | - | -$15.30 K(-31.1%) | -$92.10 K(+19.9%) |
| Mar 2008 | - | -$22.20 K(-10.5%) | -$76.80 K(+40.7%) |
| Dec 2007 | -$61.50 K | -$24.80 K(-16.8%) | -$54.60 K(+83.2%) |
| Sept 2007 | - | -$29.80 K | -$29.80 K |
FAQ
- What is Cocrystal Pharma annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Cocrystal Pharma?
- What is Cocrystal Pharma annual EBITDA year-on-year change?
- What is Cocrystal Pharma quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Cocrystal Pharma?
- What is Cocrystal Pharma quarterly EBITDA year-on-year change?
- What is Cocrystal Pharma TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Cocrystal Pharma?
- What is Cocrystal Pharma TTM EBITDA year-on-year change?
What is Cocrystal Pharma annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of COCP is -$21.16 M
What is the all time high annual EBITDA for Cocrystal Pharma?
Cocrystal Pharma all-time high annual earnings before interest, taxes, depreciation & amortization is $455.80 K
What is Cocrystal Pharma annual EBITDA year-on-year change?
Over the past year, COCP annual earnings before interest, taxes, depreciation & amortization has changed by -$3.41 M (-19.21%)
What is Cocrystal Pharma quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of COCP is -$4.94 M
What is the all time high quarterly EBITDA for Cocrystal Pharma?
Cocrystal Pharma all-time high quarterly earnings before interest, taxes, depreciation & amortization is $3.00 M
What is Cocrystal Pharma quarterly EBITDA year-on-year change?
Over the past year, COCP quarterly earnings before interest, taxes, depreciation & amortization has changed by +$992.00 K (+16.71%)
What is Cocrystal Pharma TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of COCP is -$19.97 M
What is the all time high TTM EBITDA for Cocrystal Pharma?
Cocrystal Pharma all-time high TTM earnings before interest, taxes, depreciation & amortization is $716.20 K
What is Cocrystal Pharma TTM EBITDA year-on-year change?
Over the past year, COCP TTM earnings before interest, taxes, depreciation & amortization has changed by -$386.00 K (-1.97%)